根据公司同日披露的前三季度主要经营数据，前三季度，公司注射类、口服类产品营业收入均出现同比 下降。其中，前三季度，公司注射类产品实现营收7.7亿元，同比下降31.23%；口服类产品实现营收 13.59亿元，同比下降24.24%；外用类产品实现营收1.86亿元，同比增长10.38%。 公司表示，注射类产品的营业收入同比下降，营业成本较上年同期下降34.10%，主要系热毒宁注射液 销售同比下降所致。 新京报贝壳财经讯（记者丁爽）10月30日，康缘药业发布2025年第三季度报告。前三季度公司营业收入 为23.43亿元，同比下滑24.59%；归母净利润2.00亿元，同比下滑35.63%。 从单季度表现来看，2025年第三季度，康缘药业营收、利润依旧双降，其营业收入为7.01亿元，同比下 降17.42%；归母净利润5727.24万元，同比下降20.88%。 康缘药业在三季报中表示，2025年三季度，受复杂的外部环境、医药行业政策变化等多重因素影响，公 司积极应对市场环境变化，调整销售策略、加大学术推广力度，但营业收入与净利润等指标仍阶段性承 压。呼吸与感染性疾病产品受终端市场需求波动影响，核心大品种热毒宁注射液、金振口 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600557 证券简称：康缘药业 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： □是 √否 一、主要财务数据 （一）主要会计数据和财务指标 单位：元 币种：人民币 ■ 注："本报告期"指本季度初至本季度末3个月期间，下同。 追溯调整或重述的原因说明 公司2024年12月已完成江苏中新医药有限公司（以下简称"中新医药"）100%股权收购事宜，中新医药 已成为公司全资子公司，将其纳入财务报表合并范围，公司对已披露的2024年同期数据进行了追溯调 整。 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人高海鑫、主管会计工作负责人江锁成及会计机构负责人（会计主管人员）李清保证季度报告 中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 （二）非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 ■ 对公司将《公开发行证券的公司信息 ...

Core Viewpoint - The conference hosted by Kangyuan Pharmaceutical focused on the theme of "Innovating Traditional Chinese Medicine to Empower New Retail," highlighting the transformation in the pharmaceutical industry from "incremental competition" to "value co-creation" [1] Group 1: Company Strategy - Kangyuan plans to invest 30 million yuan to focus on key products such as Jinzhen Oral Liquid and Compound Nanshing Pain Relief Plaster, aiming for extensive exposure through platforms like Douyin and Xiaohongshu [1] - The company aims to establish a closed-loop marketing model that includes "precise promotion → platform traffic → store fulfillment" [1] - Kangyuan has 59 exclusive innovative drugs, 26 exclusive medical insurance drugs, and 7 exclusive essential drugs, covering various fields such as anti-infection, gynecology, orthopedics, and cardiovascular health [3] Group 2: Market Trends - The O2O market is experiencing three major trends: accelerated integration of online and offline channels, increased demand for professional pharmaceutical services, and significant growth in innovative traditional Chinese medicine products [3] - Consumers are seeking seamless purchasing experiences that combine online and offline options [3] - There is a notable rise in demand for specialized pharmaceutical services, including medication consultation and disease management [3] Group 3: Partnership and Collaboration - Kangyuan introduced a "Joint Venture Cooperation Plan," committing 30 million yuan to support partners in digital marketing activities on mainstream online platforms [4] - The company aims to create tangible economic benefits for partners through targeted advertising and personalized promotional strategies [4] - Feedback from national chain pharmacy representatives indicates confidence in Kangyuan's products and the potential for mutually beneficial partnerships [6] Group 4: Expert Insights - Industry experts highlight the significance of Kangyuan's strategic layout, which aims to build a multi-channel marketing network and enhance brand youthfulness [6] - The strategy is expected to drive data-driven precise marketing and improve user experience [6] - The initiative also aims to promote the new dissemination of traditional Chinese medicine culture in modern society [6]